Authors: Kory P, Meduri GU, Iglesias J, Varon J, Berkowitz K, Wagshul F et al. PMID: 34375047 PMCID: PMC8088823 DOI: 10.1097/MJT.0000000000001377 Abstract Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed [...]

Authors: Al-Aly Z, Xie Y, Bowe B PMID: 33887749 DOI: 10.1038/s41586-021-03553-9 Abstract The acute clinical manifestations of COVID-19 have been well characterized1,2, but the post-acute sequelae of this disease have not been comprehensively described. Here we use the national healthcare databases of the US Department of Veterans Affairs to systematically and comprehensively identify 6-month incident [...]

Authors: Lavinio A, Ercole A, Battaglini D, Magnoni S, Badenes R, Thomas W et al. PMID: 33888132 PMCID: PMC8061459 DOI: 10.1186/s13054-021-03543-3 Abstract Introduction: Critical illness from SARS-CoV-2 infection (COVID-19) is associated with a high burden of pulmonary embolism (PE) and thromboembolic events despite standard thromboprophylaxis. Available guidance is discordant, ranging from standard care to the [...]

After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials.

Authors: Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV doi: https://doi.org/10.3389/fphar.2021.652688 Abstract Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19). Fluvoxamine is also an agonist for the sigma-1 receptor, [...]

Authors: Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J PMID: 33959278 PMCID: PMC8060761 DOI: 10.1177/20499361211009385 Abstract Coronavirus disease 2019 (COVID-19) is a viral infection which can cause a variety of respiratory, gastrointestinal, and vascular symptoms. The acute illness phase generally lasts no more than 2-3 weeks. However, there is increasing evidence that a proportion of [...]

Authors: DiNicolantonio JJ, Barroso-Aranda J, McCarty MF PMID: 33875563 PMCID: PMC8057070 DOI: 10.1136/openhrt-2021-001655 Abstract Ivermectin, a drug commonly used to treat a range of parasitic infections, has been shown to halve the mortality elicited by a fatal dose of lipopolysaccharide in mice, in an oral dose (4 mg/kg) that can be extrapolated to 2–4 times the [...]

Authors: Shouman K, Vanichkachorn G, Chesire WP, Suarez MD, Shelly S PMID: 33860871 PMCID: PMC8050227 DOI: 10.1007/s10286-021-00803-8 Abstract Purpose: Post-COVID-19 syndrome is a poorly understood aspect of the current pandemic, with clinical features that overlap with symptoms of autonomic/small fiber dysfunction. An early systematic analysis of autonomic dysfunction following COVID-19 is lacking and may provide [...]

Authors: Porter C, Favara M, Scott D, Craske MG, Stein A PMID: 33858874 PMCID: PMC8053815 DOI: 10.1136/bmjopen-2021-049653 Abstract Objective: To provide evidence on the effect of the COVID-19 pandemic on the mental health of young people who grew up in poverty in low/middle-income countries (LMICs). Design: A phone survey administered between August and October 2020 [...]

Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.